Melan-A Antibody (D-6): sc-376642

Melan-A Antibody (D-6) is a mouse monoclonal IgG1 light chain antibody that detects Melan-A in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Melan-A, also known as MART-1, is a crucial melanocyte differentiation antigen predominantly expressed in melanomas, melanocyte cell lines, and retinal tissues. Melan-A′s significance lies in its role as a target for cytotoxic T lymphocytes, which are essential for the immune response against melanoma. Melan-A peptide is recognized by a majority of HLA-A2-restricted tumor-infiltrating lymphocytes in melanoma patients, highlighting Melan-A′s potential as a candidate for antigen-specific immunotherapy. The ability to generate anti-melanoma cytotoxic T lymphocytes using Melan-A peptides underscores Melan-A′s importance in developing targeted cancer therapies. Anti-Melan-A antibody (D-6) serves as a valuable tool for researchers investigating the mechanisms of melanoma and exploring innovative treatment strategies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Melan-A Antibody (D-6) References:

1. Expression of melanocyte-associated markers gp-100 and Melan-A/MART-1 in angiomyolipomas. An immunohistochemical and rt-PCR analysis.  |  Jungbluth, AA., et al. 1999. Virchows Arch. 434: 429-35. PMID: 10389626
2. Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of melan-A/MART-1.  |  Ramirez-Montagut, T., et al. 2000. Clin Exp Immunol. 119: 11-8. PMID: 10606959
3. Evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma: higher diagnostic accuracy with Melan-A and MART-1 compared with S-100 protein and HMB-45.  |  Shidham, VB., et al. 2001. Am J Surg Pathol. 25: 1039-46. PMID: 11474288
4. Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1.  |  Saleh, FH., et al. 2001. Int J Cancer. 94: 551-7. PMID: 11745443
5. Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse.  |  Triozzi, PL., et al. 2005. J Immunother. 28: 382-8. PMID: 16000957
6. Melan-A positive dermal cells in malignant melanoma in situ.  |  Danga, ME., et al. 2015. J Cutan Pathol. 42: 388-93. PMID: 25726939
7. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.  |  Valmori, D., et al. 1998. J Immunol. 160: 1750-8. PMID: 9469433
8. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus.  |  Butterfield, LH., et al. 1998. J Immunol. 161: 5607-13. PMID: 9820539
9. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.  |  Rosenberg, SA., et al. 1998. J Natl Cancer Inst. 90: 1894-900. PMID: 9862627

The preferred Melan-A antibody is Melan-A Antibody (A103): sc-20032.